CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
vorinostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00262834
NCT00262834Phase 2Completed
CompareCT.gov

A Pilot Study Evaluating Surrogates of Response to Short Term Oral Suberoylanilide Hydroxamic Acid (SAHA) in Women With Newly Diagnosed Breast Cancer

National Cancer Institute (NCI)·interventional·Posted Dec 7, 2005·Updated Feb 19, 2020

In Brief

A Phase 2 clinical trial evaluating vorinostat and conventional surgery for Breast Cancer and 3 related conditions. Completed, enrolled 54 participants across 1 site.

Detailed Summary

This phase II trial is studying how well vorinostat works in treating women who are undergoing surgery for newly diagnosed stage I, stage II, or stage III breast cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat before surgery may shrink the tumor so that it can be removed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 7, 2005
Enrollment StartOct 1, 2005
Primary CompletionOct 1, 2008
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 20.6 years ago

Interventions

vorinostatdrug

Given orally, conventional surgery to follow.

conventional surgeryother

Undergo conventional surgery